Immune globulin 10% - Grifols

Drug Profile

Immune globulin 10% - Grifols

Alternative Names: Gammaked; Gamunex; Gamunex-C; Gamunex-IGIV; IGIV; IGIV-C; Intravenous gammaglobulin; IVIG; TAL-05-0002

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; Grifols; Kedrion
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Immune thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Myasthenia gravis
  • Discontinued Multiple sclerosis

Most Recent Events

  • 25 Apr 2017 Grifols Biologicals plans a phase II trial for Diabetic neuropathies in USA (NCT02915263)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Jul 2015 Phase-II clinical trials in Myasthenia gravis in USA, Lithuania and Estonia (IV) (NCT02473952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top